Position in DTIL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$26,229
+$6,390 QoQ
Shares Held
4,769
0.0% QoQ
Ownership
0.018%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#53
of 78 holders
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Common Shares in DTIL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Allworth Financial LP holds $21,501,509 across 296 Biotechnology names. DTIL ranks #69 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
15,803 | $7,056,671 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
36,244 | $2,342,449 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,991 | $2,310,966 | |
| 4 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
3,562 | $1,864,600 | |
| 5 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
26,462 | $655,199 | |
| 6 | CRSP |
CRISPR Therapeutics AG
|
11,016 | $524,031 | |
| 7 | INCY |
Incyte Corp
|
4,834 | $454,976 | |
| 8 | EXEL |
Exelixis, Inc.
|
10,084 | $432,502 |
All Filings in DTIL
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $26,229 | 4,769 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $19,839 | 4,769 | Shares | Sole | 2026-02-05 | |
| 2025-09-30 | $26,324 | 4,769 | Shares | Sole | 2025-12-02 | |
| 2025-06-30 | $20,029 | 4,769 | Shares | Sole | 2025-08-07 | |
| 2025-03-31 | $22,748 | 4,769 | Shares | Sole | 2025-04-30 | |
| 2024-12-31 | $18,169 | 4,769 | Shares | Sole | 2025-01-30 | |
| 2024-09-30 | $42,730 | 4,769 | Shares | Sole | 2024-10-23 | |
| 2024-06-30 | $46,402 | 4,769 | Shares | Sole | 2024-07-24 | |
| 2024-03-31 | $64,667 | 4,769 | Shares | Sole | 2024-04-25 | |
| No filing history on record for this holder in this stock. | ||||||